European review for medical and pharmacological sciences
Cure8 research brief
Why This Matters
The PD‑1/PD‑L1 pathway helps suppress harmful inflammation in IBD but can later allow colorectal tumors to avoid immune attack; understanding this balance matters for patients concerned about long‑term cancer risk and for treatment choices in CRC where PD‑1 inhibitors are used.
Who Should Pay Attention
Clinicians, researchers, and patients interested in IBD, colorectal cancer, or cancer immunotherapy.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The review describes how PD‑1/PD‑L1 signaling supports immune tolerance in early intestinal inflammation (relevant to IBD) but can later enable tumor immune escape during progression to colorectal cancer.
It summarizes current monoclonal antibody therapies targeting PD‑1/PD‑L1, notes use in mismatch repair‑deficient CRC, and discusses combination strategies and mechanisms of resistance. The paper is a literature review (abstract-level in the source) rather than new clinical trial data; it synthesizes existing studies and ongoing trial evidence.
Keep In Mind
This source is a journal review (abstract-level content). It synthesizes existing studies and ongoing trials but does not present new primary trial results. Treatment decisions require individualized clinical evaluation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEuropean review for medical and pharmacological sciences
AuthorsGrimaldi RM, Balestrero FC, Meggiolan A +3 more
Study typeReview, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Cell cycle dysregulation: a central hub in colitis-associated colorectal carcinogenesis.
The review connects molecular cell-cycle changes to the progression from chronic IBD to colorectal cancer, pointing to pathways and cell-cycle regulators that could become prevention or treatment targets for...
Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.
IBD and other lower-GI disorders may benefit from oral hydrogel platforms that improve local drug delivery while deliberately engaging the gut microbiota. Understanding this research direction helps patients and...
Nanoparticle technologies in the diagnosis and therapy of gastrointestinal diseases: Progress, challenges, and future directions.
Nanoparticle technologies could eventually enable more targeted drug delivery and improved imaging for IBD and related GI diseases, which may lead to better diagnosis and less systemic side effects. However, translation...